1048007-93-7 | Masitinib mesylate

Packsize	Purity	Availability	Price	Discounted Price
5mg	97%	in stock	$34.00	$24.00
25mg	97%	in stock	$62.00	$44.00
100mg	97%	in stock	$131.00	$92.00
250mg	97%	in stock	$211.00	$148.00
1g	97%	in stock	$511.00	$358.00
5g	97%	in stock	$1,505.00	$1,054.00
10g	97%	in stock	$2,500.00	$1,750.00

Description

• Catalog Number: AE11269
• Chemical Name: Masitinib mesylate
• CAS Number: 1048007-93-7
• Molecular Formula: C29H34N6O4S2
• Molecular Weight: 594.7481
• MDL Number: MFCD12546334
• SMILES: CS(=O)(=O)O.CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C

Computed Properties

• Complexity: 788
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7

Upstream Synthesis Route

Masitinib mesylate is a versatile compound widely used in chemical synthesis for its unique properties and applications. One of the primary applications of Masitinib mesylate in chemical synthesis is as a catalyst in organic reactions. It serves as an efficient catalyst in various transformations, such as Suzuki-Miyaura cross-coupling reactions, Heck reactions, and asymmetric hydrogenation reactions.Furthermore, Masitinib mesylate can also be employed as a reagent in the construction of complex molecular scaffolds due to its ability to facilitate the formation of C-C and C-N bonds. This makes it a valuable tool in the synthesis of pharmaceutical intermediates and natural products.In addition to its catalytic and reagent properties, Masitinib mesylate can act as a chiral ligand in metal-catalyzed reactions, enabling the enantioselective synthesis of various chiral molecules. Its high selectivity and efficiency make it a popular choice for the preparation of optically pure compounds in asymmetric synthesis.Overall, Masitinib mesylate plays a crucial role in advancing the field of chemical synthesis by enabling the efficient and selective formation of complex molecules with diverse applications in pharmaceuticals, agrochemicals, and materials science.

Literature

• In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.

  Veterinary and comparative oncology 20120901

• Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.

  Veterinary and comparative oncology 20120901

• Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

  European journal of haematology 20120701

• Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.

  Veterinary and comparative oncology 20120601

• Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.

  Investigational new drugs 20120401

• Stevens-Johnson Syndrome induced by masitinib.

  Acta dermato-venereologica 20120301

• [KIT and KIT: from biology to clinical use].

  Bulletin du cancer 20120201

• Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

  Veterinary journal (London, England : 1997) 20120101

• The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.

  International archives of allergy and immunology 20120101

• Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

  BMC neurology 20120101

• Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.

  Veterinary dermatology 20111201

• Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.

  Journal of surgical oncology 20111201

• Stratified medicine in selecting biologics for the treatment of severe asthma.

  Current opinion in allergy and clinical immunology 20110201

• Safety of masitinib mesylate in healthy cats.

  Journal of veterinary internal medicine 20110101

• Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

  PloS one 20110101

• Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

  American journal of hematology 20101201

• Clinical trial on the efficacy of masitinib in canine IBD.

  The Veterinary record 20101106

• Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.

  American journal of veterinary research 20101101

• Churg and Strauss vasculitis in the course of masitinib treatment: a first report.

  Allergy 20100801

• Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.

  Cancer chemotherapy and pharmacology 20100701

• [Focus on GIST management].

  Bulletin du cancer 20100601

• Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

  European journal of cancer (Oxford, England : 1990) 20100501

• Masitinib for the treatment of canine atopic dermatitis: a pilot study.

  Veterinary research communications 20100101

• Drug-induced minimal change nephropathy in a dog.

  Journal of veterinary internal medicine 20100101

• Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

  PloS one 20100101

• 'Masitinib' is safe and effective for the treatment of canine mast cell tumors.

  Journal of veterinary internal medicine 20100101

• Pharmacokinetics of masitinib in cats.

  Veterinary research communications 20091201

• Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

  European journal of cancer (Oxford, England : 1990) 20090901

• Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

  Allergy 20090801

• Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

  Arthritis research & therapy 20090101

• More about masitinib.

  Arthritis research & therapy 20090101

• Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

  PloS one 20090101

• [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

  Bulletin du cancer 20080101

• Masitinib is safe and effective for the treatment of canine mast cell tumors.

  Journal of veterinary internal medicine 20080101